Cadrenal Therapeutics, Inc. Common Stock

NasdaqCM CVKD

Cadrenal Therapeutics, Inc. Common Stock Market Capitalization on January 14, 2025: USD 28.50 M

Cadrenal Therapeutics, Inc. Common Stock Market Capitalization is USD 28.50 M on January 14, 2025, a 50.75% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Cadrenal Therapeutics, Inc. Common Stock 52-week high Market Capitalization is USD 43.89 M on January 31, 2024, which is 53.99% above the current Market Capitalization.
Cadrenal Therapeutics, Inc. Common Stock 52-week low Market Capitalization is USD 9.38 M on April 16, 2024, which is -67.09% below the current Market Capitalization.
Cadrenal Therapeutics, Inc. Common Stock average Market Capitalization for the last 52 weeks is USD 17.67 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: CVKD

Cadrenal Therapeutics, Inc. Common Stock

CEO	Mr. Quang X. Pham
IPO Date	Jan. 20, 2023
Location	United States
Headquarters	822 A1A North
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Key trends

Past 5 years